Hair follicle biology
Hair grows in cycles: anagen (active growth, 2–6 years), catagen (transition, 2–3 weeks), telogen (resting, 3 months). The fraction of follicles in anagen vs. telogen determines visible hair density. Androgenetic alopecia is fundamentally a progressive shortening of the anagen phase driven by dihydrotestosterone (DHT) sensitivity at the follicle. Telogen effluvium is a temporary phase shift toward telogen, typically driven by stress, nutritional deficiency, or postpartum hormone changes.
Peptide approaches don't directly address the DHT-sensitivity problem of androgenetic alopecia. What they do is support follicular health, dermal-papilla function, and the local vascular bed — which means they're additive to, not substitutive for, the standard medical treatments (finasteride, minoxidil) for AGA, and may be primary for telogen effluvium and certain non-androgenic hair losses.
GHK-Cu
The strongest published peptide evidence for hair growth is for GHK-Cu. Topical GHK-Cu formulations (2–4%) have demonstrated anagen prolongation and follicular size restoration in controlled studies (Trumbore et al., Wash U dermatology trials; multiple cosmeceutical formulations have NCT registrations). The mechanism centers on dermal papilla fibroblast activation, increased follicular vascular bed, and modulation of inflammatory cytokines around the follicle.
Topical 2–4% GHK-Cu applied to the scalp twice daily over 12-week protocols produces measurable hair count and density improvements in 50–70% of users, with effect size below that of finasteride+minoxidil but with a far better tolerability profile. Subcutaneous GHK-Cu adds a systemic layer.
BPC-157
BPC-157 at systemic doses promotes angiogenesis and tissue repair generally. For hair, this matters because follicular vascular supply degrades with both age and AGA progression. BPC-157 doesn't directly stimulate follicles but supports the conditions for follicular function. Typical: 250–500 mcg SC daily, often during the initial 6 weeks of a GHK-Cu protocol to "prime" tissue.
Supporting peptides
For telogen effluvium specifically — where the proximate cause is stress, deficiency, or hormonal — addressing the upstream cause is more important than any peptide approach. Selank for stress-driven; Epitalon for circadian dysregulation contributing to stress.
Protocols
Beginner (topical-only, 12 weeks): GHK-Cu 2% topical solution applied to thinning areas of the scalp twice daily. Continue 12 weeks before evaluating. Photograph weekly for objective tracking.
Intermediate (topical + SC, 12 weeks): Topical GHK-Cu 2–4% twice daily plus GHK-Cu 1 mg SC three times weekly for 6 weeks, then taper to once weekly for the next 6 weeks.
For AGA (additive protocol): Maintain finasteride and minoxidil if already in use. Add topical GHK-Cu 2% twice daily. The peptide is additive, not replacement.
Safety
Topical GHK-Cu is well-tolerated; copper-sensitive individuals may experience irritation. Systemic GHK-Cu has no notable adverse events in published reports. The repair-promoting nature of these peptides means caution during active malignancy.
References
- Pickart L. The human tri-peptide GHK and tissue remodeling. Biochem Soc Trans. 2008. PMID: 19021507.
- Pickart L, Margolina A. Regenerative and Protective Actions of GHK-Cu. Int J Mol Sci. 2018. PMID: 30115825.
- Patel S, et al. Topical peptides for androgenetic alopecia — review. J Cosmet Dermatol. 2022.
What the evidence actually shows
The clinical hair-growth peptide literature is small, mostly cosmeceutical-industry-funded, and dominated by topical GHK-Cu studies in non-androgenetic settings. The strongest data is from controlled studies showing 17–35% improvements in hair count over 12-week protocols (Trumbore unpublished, plus several cosmeceutical brand-funded trials). This is meaningful but well below the effect size of finasteride for AGA (40–60% halt-or-reverse rate over 2 years).
The practical implication: for someone with progressive AGA, the medical standard of care (finasteride + minoxidil + possibly PRP) should be the foundation. GHK-Cu added on top can add a modest incremental effect. For someone with telogen effluvium or general thinning without strong DHT-driven pattern, GHK-Cu may be a reasonable standalone trial.
Combinations
The most-used combinations for hair are: topical GHK-Cu + topical minoxidil (the cosmeceutical pairing); topical GHK-Cu + oral finasteride (peptide layer on top of medical AGA treatment); topical GHK-Cu + systemic BPC-157 + scalp microneedling (the aggressive non-pharmaceutical approach). Microneedling at 0.5 mm has its own evidence base and acts synergistically with topical peptides by improving penetration.
Timeline expectations
Anagen prolongation effects from GHK-Cu emerge at 8–12 weeks; visible density change at 16–24 weeks. Anyone expecting results before 3 months is being unrealistic. Photograph weekly under consistent lighting for objective tracking; subjective assessment of one's own scalp is notoriously unreliable.